Redmile Group’s Pulmonx LUNG Stock Holding History

Redmile Group’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-275,000	Closed	-$19M	–	92
2020 Q4	$19M	Buy	+275,000	New	+$13.5M	0.23%	64

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

AWGLSCP

ABG-WTT Global Life Science Capital Partners Central, Hong Kong, Hong Kong $12.3M AUM 3.13% 1-Year Est. Return

Redmile Group's LUNG Position: Q1 2021 in Review

Redmile Group sold out of Pulmonx (LUNG) in Q1 2021, closing a stake of 275,000 shares — an estimated $19M sold.

Redmile Group first reported a position in LUNG in Q4 2020 and held it in 1 quarter. The position peaked at $19M in Q4 2020. 110 funds tracked by Wall St. Rank hold LUNG as of Q1 2021.

Redmile Group reported no remaining Pulmonx position as of Q1 2021 after selling out during the quarter.
Redmile Group sold 275,000 Pulmonx shares in Q1 2021, an estimated $19M.
Redmile Group first reported a position in Pulmonx in Q4 2020 and held it in 1 quarter.
Redmile Group's Pulmonx position peaked at $19M in Q4 2020.
110 funds tracked by Wall St. Rank held Pulmonx as of Q1 2021.

Based on Redmile Group's 13F filing for Q1 2021, filed 17 May 2021.